

SUPPLEMENTAL PRELIMINARY AMENDMENT
U.S. Appln. No. 10/568,671

REMARKS

The specification has been amended for the purpose of clarification. Claim 4 has been amended to incorporate the subject matter of original Claim 5, and to be placed in independent form.

Support for Claim 16 can be found at page 16, line 20 to page 17, line 1 of the present specification.

Newly added Claim 17 is directed to the composition of original Claim 4, being a pharmaceutical composition for human muscosal immunostimulation (see Claim 8).

Newly added Claim 18 is directed to the composition of original Claim 4, being a pharmaceutical composition for promoting human IgA production (see Claim 10).

Hence, the amendments to the specification and claims, and the addition of new Claims 16-18 do not constitute new matter, and thus entry is respectfully requested.


The Examiner is invited to contact the undersigned at the below listed number on any questions which might arise.

Respectfully submitted,

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860



Gordon Kit

Registration No. 30,764

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: February 8, 2006